Fusion Pharmaceuticals Inc. (FUSN)

NASDAQ: FUSN · IEX Real-Time Price · USD

21.25

+0.01 (0.05%)

At close: Apr 18, 2024, 4:00 PM

21.35

+0.10 (0.47%)

After-hours: Apr 18, 2024, 6:57 PM EDT

Fusion Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Revenue	2.07	1.46	1.44	0	0	0	0
Revenue Growth (YoY)	41.55%	1.46%	-	-	-	-	-
Gross Profit	2.07	1.46	1.44	0	0	0	0
Selling, General & Admin	31.2	30.6	27.1	20.74	7.59	3.22	1.62
Research & Development	70.1	58.9	56.36	17.19	10.63	6.88	5.37
Operating Expenses	101.3	89.5	83.46	37.94	18.22	10.1	6.99
Operating Income	-99.23	-88.03	-82.02	-37.94	-18.22	-10.1	-6.99
Interest Expense / Income	5.17	1.8	0	0	0.58	0	0
Other Expense / Income	-10.29	-0.39	-0.85	37.79	-2.86	1.37	-0.72
Pretax Income	-94.11	-89.45	-81.17	-75.72	-15.94	-11.47	-6.26
Income Tax	0.79	-1.84	-0.12	2.61	0.25	0.18	0
Net Income	-94.9	-87.61	-81.05	-78.33	-16.19	-11.65	-6.26
Preferred Dividends	0	0	0	1.38	0	0	0
Net Income Common	-94.9	-87.61	-81.05	-79.72	-16.19	-11.65	-6.26
Shares Outstanding (Basic)	66	44	43	22	2	2	2
Shares Outstanding (Diluted)	66	44	43	22	2	2	2
Shares Change	49.98%	2.70%	93.34%	1050.20%	2.28%	-	-
EPS (Basic)	-1.45	-2.00	-1.90	-3.62	-8.45	-6.22	-3.34
EPS (Diluted)	-1.45	-2.00	-1.90	-3.62	-8.45	-6.22	-3.34
Free Cash Flow	-85.69	-75.42	-77.23	-30.89	-14.15	-10.99	-6.22
Free Cash Flow Per Share	-1.31	-1.72	-1.81	-1.40	-7.38	-5.87	-3.32
Gross Margin	100.00%	100.00%	100.00%	-	-	-	-
Operating Margin	-4798.45%	-6025.60%	-5695.49%	-	-	-	-
Profit Margin	-4588.83%	-5996.71%	-5628.26%	-	-	-	-
Free Cash Flow Margin	-4143.71%	-5162.08%	-5363.26%	-	-	-	-
EBITDA	-85.08	-85.6	-79.46	-75.22	-15.07	-11.36	-6.24
EBITDA Margin	-4114.12%	-5858.93%	-5517.92%	-	-	-	-
Depreciation & Amortization	3.86	2.05	1.71	0.51	0.29	0.11	0.02
EBIT	-88.94	-87.65	-81.17	-75.72	-15.36	-11.47	-6.26
EBIT Margin	-4300.97%	-5999.18%	-5636.46%	-	-	-	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).